HAE Patients in US Favored Oral Prophylactic in 2018 Survey

HAE Patients in US Favored Oral Prophylactic in 2018 Survey

287102

HAE Patients in US Favored Oral Prophylactic in 2018 Survey

People with hereditary angioedema (HAE) would prefer an oral medication that could prevent their attacks, even when satisfied with their current treatment, a survey of patients in the U.S. reports. The study, “Hereditary angioedema patients would prefer newer-generation oral prophylaxis,” was published in the Journal of Drug Assessment. BioCryst Pharmaceuticals, which developed and markets Orladeyo (berotralstat), an oral HAE preventive treatment recently approved in the U.S. and Japan, and available in the U.K., funded the study.…

You must be logged in to read/download the full post.